Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data Shares Rise on Plans for 3-for-2 Stock Split

NEW YORK (GenomeWeb News) - Clinical Data’s board of directors yesterday approved a 3-for-2 stock split that will give company stockholders one new share of common stock for every two shares they own.
 
The news drove the company's share price up nearly 13 percent to close at $34.38 yesterday. In late morning trading today, the company's shares had pulled back slightly to $33.96. 
 
The split will occur Sept. 24, and the dividends will be distributed on Oct. 2, the company said.
 
When the split is complete, the company will have a total of around $20.5 million shares outstanding.
 
Company President and CEO Drew Fromkin said the split "reflects the confidence we have in the prospects of our company," and said it is "an opportunity to broaden our base of investors by making our stock more accessible while improving its liquidity.”

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.